Final Program - American Society of Gene & Cell Therapy

Program Schedule, Friday, May 17, 2013
Scientific Symposium 310
9:45 am - 11:45 am
ROOM: BALLROOM D
Cancer Gene and Cell Therapy: Results from Clinical Trials
CO-CHAIRS: Evanthia Galanis, MD, DSc and Juan F. Vera, MD
SPEAKERS
Svend O. Freytag, PhD
Randomized, Controlled, Phase 2 Trial of Oncolytic Adenovirus-mediated Suicide Gene Therapy Plus IMRT
Versus IMRT Alone in neWly-diagnosed, Intermediate-risk Prostate Cancer
We have developed a multi-modal, gene therapy-based approach for the treatment of cancer involving an oncolytic adenovirus,
suicide gene therapy and radiation therapy. We have evaluated the safety and eficacy of our approach in six clinical trials, including
a randomized, controlled phase 2 trial in prostate cancer. The results of these clinical studies will be presented and the lessons
learned discussed.
Evanthia Galanis, MD, DSc
Oncolytic Measles Virus Strains in Cancer Treatment Trials: An Update
Measles virus is a negative strand RNA virus (paramyxovirus) with oncolytic properties. The signiicant preclinical activity of MV-
Edmonston vaccine strains against multiple different animal tumor models, their potent bystander effect, their selectivity against
tumor cells, and their ability to retain their oncolytic properties when engineered and retargeted, makes them a promising oncolytic
platform. Two trackable engineered measles virus strain derivatives are currently in clinical testing; a derivative expressing the
human carcinoembryonic antigen (MV-CEA) and a strain expressing the human sodium iodine symporter (MV-NIS). Phase I/II trials
are ongoing or have been completed in ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma and head and
neck cancer and a phase I/II trial of mesenchymal stem cell delivery will be activated later this year. Clinical data to date, challenges
in clinical applications of oncolytic measles virus strains and preclinical data supporting future translational directions will be
discussed.
Friday, May 17, 2013
Renier J. Brentjens, MD, PhD
CAR Modiied T-cells, From the Bench to the Bedside
T cells may be genetically modiied to express artiicial T cell receptors, termed chimeric antigen receptors or CARs targeted to
tumor associated antigens. Previous work in preclinical models has demonstrated the potential of this approach in targeting T
cells to systemic tumor and in turn eradicating tumor. More recently, we and others have successfully moved this technology to the
clinical setting demonstrating early very promising responses with CD19 targeted CAR modiied T cells in patients with relapsed
B cell malignancies including acute lymphoblastic and chronic lymphocytic leukemias as well as indolent B cell non-Hodgkins
lymphomas. However, limitations to this adoptive T cell approach need to be addressed before this approach may be successfully
optimized to B cell malignancies and further expanded to other cancers targeting other tumor associated antigens. One such an
approach is the design of “armored CAR” T cells additionally modiied to express cytokines or co-stimulatory ligands to enhance in
vivo cytotoxicity as well as persistence of CAR modiied T cells following infusion.
Stephen Gottschalk, MD
Cell Therapies for Solid Tumors: Successes and Challenges
The outcome for patients with advanced solid tumors has not signiicantly improved over the last 2 decades. Thus, new targeted
therapies are needed to improve current outcomes, and T-cell immunotherapy has the potential to fulill this need. In my talk I will
review i) the use of Epstein-Barr virus (EBV)-speciic T cells to treat patients with advanced stage EBV+ nasopharyngeal carcinoma,
ii) our recent studies to target solid tumors and their supporting stroma with chimeric antigen receptor (CAR) T cells, and iii) novel
approaches to render T cells speciic for solid tumor antigens.
58
Final Program SALT LAKE CITY, UTAH May 15–18, 2013